Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

Company Overview - Absci Corporation is a data-first generative AI drug creation company focused on advancing drug discovery through generative design to create better biologics for patients more quickly [3] - The company utilizes its Integrated Drug Creation™ platform, which combines advanced AI models with a synthetic biology data engine, to rapidly design innovative therapeutics targeting challenging therapeutic areas [3] Upcoming Financial Reporting - Absci will report its business updates and financial results for the first quarter of 2025 after market close on May 13, 2025 [1] - A conference call will be held at 4:30 p.m. Eastern Time to discuss the business developments and financial results, with a live audio webcast available on the company's investor relations website [2] Product Pipeline - Absci is advancing its pipeline of AI-designed therapeutics, including ABS-101, aimed at treating inflammatory bowel disease (IBD), and ABS-201, which targets hair regrowth for androgenetic alopecia [3]